Chromatographic assays of drug oxidation by human cytochrome P450 3A4

被引:0
|
作者
Christal D Sohl
Qian Cheng
F Peter Guengerich
机构
[1] Vanderbilt University School of Medicine,Department of Biochemistry and Center in Molecular Toxicology
来源
Nature Protocols | 2009年 / 4卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Cytochrome P450 enzymes (P450s) are heme-thiolate mono-oxygenases involved in the oxidation of many endogenous and exogenous substrates. Herein, we describe two protocols for measuring the activity of a key enzyme of drug metabolism, P450 3A4. In this protocol, the substrate is incubated with human liver microsomes, the reaction is quenched, and the substrates and products are extracted and subjected to liquid chromatography (LC) separation and detection. Oxidation of the calcium-channel blocker nifedipine is measured using UV–Vis spectroscopy in-line with high performance liquid chromatography (HPLC). 6β-Hydroxytestosterone formation from testosterone is measured by HPLC coupled to mass spectrometry (MS). Both of these procedures are rapid, requiring 2 h or less, and can be used to confirm and measure P450 3A4 activity and can also be used as a guide for developing other assays for measuring P450 catalysis. The separation strategy described here is more rapid than many available methods, except when ultra-performance liquid chromatography (UPLC) is used.
引用
收藏
页码:1252 / 1257
页数:5
相关论文
共 50 条
  • [1] Chromatographic assays of drug oxidation by human cytochrome P450 3A4
    Sohl, Christal D.
    Cheng, Qian
    Guengerich, F. Peter
    NATURE PROTOCOLS, 2009, 4 (09) : 1252 - 1257
  • [2] Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation
    Kudo, S
    Odomi, M
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 54 (03) : 253 - 259
  • [3] Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation
    S. Kudo
    M. Odomi
    European Journal of Clinical Pharmacology, 1998, 54 : 253 - 259
  • [4] Substrates of human hepatic cytochrome P450 3A4
    Li, AP
    Kaminski, DL
    Rasmussen, A
    TOXICOLOGY, 1995, 104 (1-3) : 1 - 8
  • [5] Inhibition of Human Cytochrome P450 3A4 by Cholesterol
    Shinkyo, Raku
    Guengerich, F. Peter
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (21) : 18426 - 18433
  • [6] Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4
    Sevrioukova, Irina F.
    Poulos, Thomas L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (03) : 486 - 491
  • [7] Structures of cytochrome P450 3A4
    Scott, EE
    Halpert, JR
    TRENDS IN BIOCHEMICAL SCIENCES, 2005, 30 (01) : 5 - 7
  • [8] Cytochrome P450 3A4 drug interaction profile of tofacitinib
    Krishnaswami, Sriram
    Lamba, Manisha
    Gupta, Pankaj
    Takiya, Liza
    Wang, Ronnie
    Kaplan, Irina
    Salageanu, Joanne
    Tarabar, Sanela
    Alvey, Christine
    Ndongo, Marie-Noella
    PHARMACOTHERAPY, 2012, 32 (10): : E240 - E240
  • [9] Involvement of human cytochrome P450 3A4 in the metabolism of vamidothion
    Mehmood, Z
    Kelly, DE
    Kelly, SL
    PESTICIDE SCIENCE, 1996, 46 (03): : 287 - 290
  • [10] Testosterone 1β-hydroxylation by human cytochrome P450 3A4
    Krauser, JA
    Voehler, M
    Tseng, LH
    Schefer, AB
    Godejohann, M
    Guengerich, FP
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 2004, 271 (19): : 3962 - 3969